1. Scrip
  2. >>Focus On Asia
  3. >>South Korea

LegoChem Brings Late Christmas Cheer With $1.7bn ADC Deal

Janssen Gets Worldwide Rights To Trop2-Directed ADC

 
• By Jung Won Shin

LegoChem Biosciences has sealed yet another sizable out-licensing agreement with a global big pharma firm, this time with Janssen, underlining the continued keen global interest in ADCs.

christmas gift
LegoChem/Janssen ADC Deal Biggest So Far For Korean Firm • Source: Shutterstock

More signs of improvement in South Korean biopharma alliances emerged right at the end of 2023, with LegoChem Biosciences, Inc. announcing an up to $1.7bn antibody-drug conjugate (ADC) deal with Janssen Biotech Inc. just after Christmas. 

Key Takeaways

  • Deal marks another major deal with a global big pharma for LegoChem and the biggest out-licensing so far by a Korean biopharma firm.

The much anticipated out-licensing agreement for worldwide development and commercialization rights to the Korean biotech’s Trop2-directed oncology ADC LCB84 (Trop2-MMAE)...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from South Korea

Q2 Korea Biotech Roundup: Licensing Deals End, Trials Progress, IPOs Recover

 
• By Jung Won Shin

Aside from several sizable global out-licensing deals, South Korean bioventures saw a cancellation of other alliances, updated their pipelines with losses and gains and reported clinical trial progress in the second quarter, while domestic IPO sentiment also improved.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By Jung Won Shin

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Bitcoin Player Parataxis To Acquire Bridge Biotherapeutics After IPF Failure

 
• By Jung Won Shin

After the failure of its lead asset in a Phase II trial earlier this year, Korea's Bridge Biotherapeutics has accepted an acquisition offer from bitcoin group Parataxis.

Profit-Sharing AI Model Proposed To Boost Korean Drug R&D

 
• By Jung Won Shin

A differentiated profit-sharing model to accelerate the use of AI in drug development using clinical and patient data is being proposed in South Korea, but the idea faces multiple practical challenges

More from Focus On Asia

Sun’s Alopecia Treatment Debuts In US - Can It Make Up For Lost Time?

 
• By Anju Ghangurde

Sun’s Leqselvi goes up against Lilly's Olumiant and Pfizer's Litfulo, which currently has the broadest label, in the US alopecia market. Can it shake things up early, amid growing activity in the space with several new mechanisms of action being investigated?

Activist Investor Vs. Japan Pharma: ASKA Plans Poison Pill As Dalton Pushes For MBO

 
• By Lisa Takagi

While ASKA plans to dilute the holding of largest investor Dalton by issuing new shares, the US investment firm continues to push a management buyout option to the mid-sized Japanese pharma company.

China’s Mid-Cap Companies Thriving On Big Pharma Deals

 
• By Andrew McConaghie and Edwin Elmhirst

Big pharma is increasingly looking east to restock its pipelines, a process that is helping to forge a new generation of mid-sized R&D-based companies in China and is reflected in their stock price performance.